{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:15:10Z","timestamp":1786119310275,"version":"build-2736575974"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1097\/coc.0b013e3181a650fb","type":"journal-article","created":{"date-parts":[[2010,3,27]],"date-time":"2010-03-27T05:24:09Z","timestamp":1269667449000},"page":"242-245","source":"Crossref","is-referenced-by-count":6,"title":["A Phase I Study of Capecitabine, Irinotecan, Celecoxib, and Radiation as Neoadjuvant Therapy of Patients With Locally Advanced Rectal Cancer"],"prefix":"10.1097","volume":"33","author":[{"given":"Imtiaz","family":"Malik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farabi","family":"Hussein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munther","family":"Alqaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Bernal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Garberoglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","article-title":"Preoperative versus postoperative chemoradiotherapy for rectal cancer.","volume":"351","author":"Sauer","year":"2004","journal-title":"N Engl J Med"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0360-3016(00)00732-X","article-title":"Prognostic significance of post-chemoradiation stage following preoperative chemotherapy and radiation for advanced\/recurrent rectal cancers.","volume":"48","author":"Mohiuddin","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"8688","DOI":"10.1200\/JCO.2005.02.1329","article-title":"Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.","volume":"23","author":"Rodel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1245\/ASO.2006.03.053","article-title":"A pathologic complete response of rectal cancer to preoperative combined- modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.","volume":"13","author":"Stipa","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.coc.0000214930.78200.4a","article-title":"Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer.","volume":"29","author":"Das","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ijrobp.2006.08.065","article-title":"Association between pathologic response in metastatic lymphnodes after preoperative chemoradiation and risk of distant metastases in rectal cancer: an analysis of outcomes in a randomized trial.","volume":"67","author":"Bujko","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-6-20210128","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumors by enzymes concentrated in human liver and cancer tissues.","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0006-2952(97)00682-5","article-title":"Tumor selective delivery of 5-FU by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts.","volume":"55","author":"Ishikawa","year":"1998","journal-title":"Biochem Pharmacol"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients.","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/jnci\/88.16.1110","article-title":"Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma.","volume":"88","author":"Takebayashi","year":"1996","journal-title":"J Natl Cancer Inst"},{"key":"R12-6-20210128","first-page":"685","article-title":"Positive correlation between efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts.","volume":"58","author":"Ishikawa","year":"1998","journal-title":"Cancer Res"},{"key":"R13-6-20210128","first-page":"2948","article-title":"X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts.","volume":"10","author":"Sawada","year":"1999","journal-title":"Clin Cancer Res"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1200\/JCO.2001.19.21.4097","article-title":"Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.","volume":"19","author":"Van Custem","year":"2001","journal-title":"J Clin Oncol"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1200\/JCO.2001.19.8.2282","article-title":"Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.","volume":"19","author":"Hoff","year":"2001","journal-title":"J Clin Oncol"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1200\/JCO.2001.19.5.1501","article-title":"Irinotecan in the treatment of coloractal cancer: clinical overview.","volume":"19","author":"Vanhoefer","year":"2001","journal-title":"J Clin Oncol"},{"key":"R17-6-20210128","first-page":"3785","article-title":"Expression of cyclooxygenase-1 and -2 in human colorectal cancer.","volume":"55","author":"Sano","year":"1995","journal-title":"Cancer Res"},{"key":"R18-6-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1136\/gut.45.5.730","article-title":"Differential expression of cyclooxygenase 2 in human colorectal cancer.","volume":"45","author":"Dimberg","year":"1999","journal-title":"Gut"},{"key":"R19-6-20210128","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1097\/01.COC.0000074158.59269.9F","article-title":"COX-2 inhibitors as radiosensitizing agents for cancer therapy.","volume":"26","author":"Davis","year":"2003","journal-title":"Am J Clin Oncol"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.1997.15.1.110","article-title":"Patients preference for oral versus intravenous palliative chemotherapy.","volume":"15","author":"Liu","year":"1997","journal-title":"J Clin Oncol"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ijrobp.2005.02.046","article-title":"Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer.","volume":"63","author":"Kim","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.ijrobp.2006.05.063","article-title":"Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer.","volume":"66","author":"Krishnan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.ijrobp.2006.07.1374","article-title":"Preoperative chemoradiotherapy with capecitabine versus protracted infusion 5-Fluorouracil for rectal cancer: a matched-pair analysis.","volume":"66","author":"Das","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijrobp.2006.08.063","article-title":"Comparison of 5-fluorouracil\/leucovorin and capecitabine in preoperative chemoradiotherapy for locally advanced rectal cancer.","volume":"67","author":"Kim","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/sj.bjc.6603053","article-title":"Concurrent chemoradiation with capecitabine and weekly irinotecan as preoperative treatment for rectal cancer: results from a phase I\/II study.","volume":"94","author":"Klautke","year":"2006","journal-title":"Br J Cancer"},{"key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/sj.bjc.6603645","article-title":"Phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (Capiri-RT) as neoadjuvant treatment of locally advanced rectal cancer.","volume":"96","author":"Willeke","year":"2007","journal-title":"Br J Cancer"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1200\/JCO.2003.07.127","article-title":"Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage nonsmall cell-lung cancer.","volume":"21","author":"Altorki","year":"2003","journal-title":"J Clin Oncol"},{"key":"R28-6-20210128","first-page":"370s","article-title":"Eicosanoid modulation in advanced nonsmall cell lung cancer (NSCLC); CALGB 30203 [Abstract 7025].","volume":"24","author":"Edleman","year":"2006","journal-title":"J Clin Oncol"},{"key":"R29-6-20210128","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/1078-0432.CCR-06-0551","article-title":"Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.","volume":"13","author":"Javle","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/01.coc.0000217818.07962.67","article-title":"Retrospective study of capecitabine and celecoxib in metastatic colorectal cancer: potential benefits and COX-2 as the common mediator in pain, toxicities and survival?","volume":"29","author":"Lin","year":"2006","journal-title":"Am J Clin Oncol"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1200\/JCO.2006.07.4773","article-title":"A randomized phase II trial of docetaxel\/irinotecan and gemcitabine\/irinotecan with or without celecoxib in the second-line treatment of nonsmall cell lung cancer.","volume":"24","author":"Lilenbaum","year":"2006","journal-title":"J Clin Oncol"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"146s","DOI":"10.1200\/jco.2006.24.18_suppl.3506","article-title":"A randomized trial of first-line irinotecan\/fluoropymidine combinations with or without celecoxib in metastatic colorectal cancer (BICC-C) [Abstract 3506].","volume":"24","author":"Fuchs","year":"2006","journal-title":"J Clin Oncol"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","article-title":"Risk of cardiovascular events associated with selective COX-2 inhibitors.","volume":"286","author":"Mukherjee","year":"2001","journal-title":"JAMA"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1056\/NEJMoa050405","article-title":"Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention.","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMoa050493","article-title":"Cardiovascular events associated with rofecoxib in colorectal adenoma chemoprevention trial.","volume":"352","author":"Bresalier","year":"2005","journal-title":"N Engl J Med"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000421-201006000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:14:43Z","timestamp":1786040083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000421-201006000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0b013e3181a650fb","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}